Ashkan Shoamanesh
At this year’s World Stroke Congress (WSC), PHRI researchers presented important insights on thrombosis, brain health, arrhythmia, and heart failure.
PHRI Senior Scientist Ashkan Shoamanesh presented on the reversal of Factor Xa inhibitor in intercranial hemorrhage (ICH)- highlighting findings from the ANNEXa-I study. In a separate session on controversies in cardiac monitoring and anticoagulation, Shoamanesh also discussed findings from the ARTESiA trial on atrial fibrillation management.
PHRI Investigator Raed Joundi presented a secondary analysis of the AXIOMATIC-SSP trial on the factors affecting cognitive performance 90 days after acute ischemic stroke.
Mike Sharma
PHRI Scientist Mike Sharma addressed the role of dual antiplatelet therapies, such as rivaroxaban combined with aspirin or FXIa inhibitors, in secondary stroke prevention. He shared findings from several trials, including COMPASS and PACIFIC-Stroke, while also highlighting the ongoing OCEANIC-STROKE trial.
PHRI International Fellow Alexander Benz, introduced the new PHRI SWITCH-AF trial, a phase IV study that he will be leading with Sharma and Shoamanesh. This new multicenter randomized clinical trial will test whether switching to a Vitamin K Antagonist (VKA) in patients with atrial fibrillation and breakthrough strokes on direct oral anticoagulants (DOAC) can reduce the risk of strokes or systemic embolism compared to staying on DOAC therapy.
Back to the future? Are VKA a potential solution to lower the risk of recurrence in patients with #breakthroughstrokes despite OAC in patients with AF? @AlexanderPBenz of @PHRIresearch at @WorldStrokeOrg @ESOstroke thought provocing pic.twitter.com/X6OdAwVFpQ
— David Seiffge (@DavidSeiffge) October 24, 2024
Aristeidis Katsanos
PHRI Investigator Aristeidis Katsanos presented on the CoVasc-ICH 2 study, a randomized phase III study for reducing dependency and cardiovascular events with oral colchicine 0.5mg once daily compared with placebo in participants with spontaneous intracerebral hemorrhage and established, or risk factors for, atherosclerosis.
Katsanos was also recognized as one of the graduates from the WSO Future Stroke Leaders Programme, Cohort 2. Congratulations on this achievement!
An incredible journey coming to an end…or is it just the beginning? Congratulations to all WSO Future stroke leaders from Cohort 2! @WorldStrokeOrg #WSC2024 @PHRIresearch @McmasterStroke @MacDeptMed pic.twitter.com/ceGpz0IRxF
— Aristeidis Katsanos (@ArKatsanos) October 24, 2024
